Literature DB >> 33704566

A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompletion of concurrent chemoradiotherapy in patients with head and neck cancer.

Shun-Wen Hsueh1, Cheng-Chou Lai2, Chia-Yen Hung3,4, Yu-Ching Lin5, Chang-Hsien Lu6, Kun-Yun Yeh1, Ngan-Ming Tsang7, Yu-Shin Hung3, Pei-Hung Chang1, Wen-Chi Chou8,9.   

Abstract

BACKGROUND: Concurrent chemoradiotherapy (CCRT) treatment incompletion is a known negative prognosticator for patients with head and neck cancer (HNC). Malnutrition is a common phenomenon which leads to treatment interruption in patients with HNC. We aimed to compare the performance of three nutritional tools in predicting treatment incompletion in patients with HNC undergoing definitive CCRT.
MATERIAL AND METHODS: Three nutritional assessment tools, Mini Nutritional Assessment-Short Form (MNA-SF), Malnutritional Universal Screening Tool (MUST), and Nutritional Risk Screening 2002 (NRS-2002), were prospectively assessed prior to CCRT for HNC patients. Patients were stratified into either normal nutrition or malnourished groups using different nutrition tools. Treatment incompletion and treatment-related toxicities associated with CCRT were recorded.
RESULTS: A total of 461 patients were included in the study; malnourished rates ranged from 31.0 to 51.0%. The CCRT incompletion rates were 4.9-6.3% and 14.5-18.2% for normal nutrition patients and malnourished patients, respectively. The tools had significant correlations with each other (Pearson correlation 0.801-0.837, p<0.001 for all) and accurately predicted the incompletion of CCRT. MNA-SF had the highest performance in predicting treatment-related toxicity, including emergency room visits, need for hospitalization, any grade III or higher hematological adverse events, and critical body weight loss, compared to the other tools.
CONCLUSIONS: MNA-SF, MUST, and NRS2002 were all shown to be competent tools for prediction of treatment incompletion and treatment-related toxicity in HNC patients undergoing CCRT. We suggest implementing nutritional assessment prior to treatment to improve the rate of treatment completion and to reduce treatment-related toxicity in HNC patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adverse event; Head and neck cancer; Nutritional assessment tool; Treatment incompletion

Year:  2021        PMID: 33704566     DOI: 10.1007/s00520-021-06140-w

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  1 in total

1.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

  1 in total
  4 in total

1.  Albumin and Neutrophil-to-Lymphocyte Ratio Score in Neoadjuvant Concurrent Chemoradiotherapy for Esophageal Cancer: Comparison With Prognostic Nutritional Index.

Authors:  William Harrison Hsueh; Shun-Wen Hsueh; Kun-Yun Yeh; Yu-Shin Hung; Ming-Mo Ho; Shinn-Yn Lin; Chen-Kan Tseng; Chia-Yen Hung; Wen-Chi Chou
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Nutrition Risk Screening and Related Factors Analysis of Non-hospitalized Cancer Survivors: A Nationwide Online Survey in China.

Authors:  Fang Wang; Qi Dong; Kang Yu; Rong-Rong Li; Ji Fu; Jia-Yu Guo; Chun-Wei Li
Journal:  Front Nutr       Date:  2022-06-21

3.  The Determination of a Consensus Nutritional Approach for Cancer Patients in Spain Using the Delphi Methodology.

Authors:  José Pablo Suárez-Llanos; Ruth Vera-García; Jorge Contreras-Martinez
Journal:  Nutrients       Date:  2022-03-28       Impact factor: 5.717

Review 4.  Current Screening Methods for the Risk or Presence of Malnutrition in Cancer Patients.

Authors:  Alessio Molfino; Giovanni Imbimbo; Alessandro Laviano
Journal:  Cancer Manag Res       Date:  2022-02-15       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.